Literature DB >> 32020683

Association of Tramadol Use With Risk of Hip Fracture.

Jie Wei1,2,3, Nancy E Lane4, Marcy B Bolster2, Maureen Dubreuil5,6, Chao Zeng2,3,7, Devyani Misra8, Na Lu2,9, Hyon K Choi2,3, Guanghua Lei7,10, Yuqing Zhang2,3.   

Abstract

Several professional organizations have recommended tramadol as one of the first-line or second-line therapies for patients with chronic noncancer pain and its prescription has been increasing rapidly worldwide; however, the safety profile of tramadol, such as risk of fracture, remains unclear. This study aimed to examine the association of tramadol with risk of hip fracture. Among individuals age 50 years or older without a history of hip fracture, cancer, or opioid use disorder in The Health Improvement Network (THIN) database in the United Kingdom general practice (2000-2017), five sequential propensity score-matched cohort studies were assembled, ie, participants who initiated tramadol or those who initiated one of the following medications: codeine (n = 146,956) (another commonly used weak opioid), naproxen (n = 115,109) or ibuprofen (n = 107,438) (commonly used nonselective nonsteroidal anti-inflammatory drugs [NSAIDs]), celecoxib (n = 43,130), or etoricoxib (n = 27,689) (cyclooxygenase-2 inhibitors). The outcome was incident hip fracture over 1 year. After propensity-score matching, the included participants had a mean age of 65.7 years and 56.9% were women. During the 1-year follow-up, 518 hip fracture (3.7/1000 person-years) occurred in the tramadol cohort and 401 (2.9/1000 person-years) occurred in the codeine cohort. Compared with codeine, hazard ratio (HR) of hip fracture for tramadol was 1.28 (95% confidence interval [CI] 1.13 to 1.46). Risk of hip fracture was also higher in the tramadol cohort than in the naproxen (2.9/1000 person-years for tramadol, 1.7/1000 person-years for naproxen; HR = 1.69, 95% CI 1.41 to 2.03), ibuprofen (3.4/1000 person-years for tramadol, 2.0/1000 person-years for ibuprofen; HR = 1.65, 95% CI 1.39 to 1.96), celecoxib (3.4/1000 person-years for tramadol, 1.8/1000 person-years for celecoxib; HR = 1.85, 95% CI 1.40 to 2.44), or etoricoxib (2.9/1000 person-years for tramadol, 1.5/1000 person-years for etoricoxib; HR = 1.96, 95% CI 1.34 to 2.87) cohort. In this population-based cohort study, the initiation of tramadol was associated with a higher risk of hip fracture than initiation of codeine and commonly used NSAIDs, suggesting a need to revisit several guidelines on tramadol use in clinical practice.
© 2020 American Society for Bone and Mineral Research. © 2020 American Society for Bone and Mineral Research.

Entities:  

Keywords:  COHORT; FRACTURE; TRAMADOL

Year:  2020        PMID: 32020683      PMCID: PMC8282603          DOI: 10.1002/jbmr.3935

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  48 in total

1.  Sensitivity Analysis in Observational Research: Introducing the E-Value.

Authors:  Tyler J VanderWeele; Peng Ding
Journal:  Ann Intern Med       Date:  2017-07-11       Impact factor: 25.391

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  Epidemiology of fractures in England and Wales.

Authors:  T P van Staa; E M Dennison; H G Leufkens; C Cooper
Journal:  Bone       Date:  2001-12       Impact factor: 4.398

Review 4.  Trends in Tramadol: Pharmacology, Metabolism, and Misuse.

Authors:  Karen Miotto; Arthur K Cho; Mohamed A Khalil; Kirsten Blanco; Jun D Sasaki; Richard Rawson
Journal:  Anesth Analg       Date:  2017-01       Impact factor: 5.108

Review 5.  Pharmacology and clinical experience with tramadol in osteoarthritis.

Authors:  W A Katz
Journal:  Drugs       Date:  1996       Impact factor: 9.546

6.  Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study.

Authors:  Til Stürmer; Kenneth J Rothman; Jerry Avorn; Robert J Glynn
Journal:  Am J Epidemiol       Date:  2010-08-17       Impact factor: 4.897

7.  Trends in hip fracture rates in Canada.

Authors:  William D Leslie; Siobhan O'Donnell; Sonia Jean; Claudia Lagacé; Peter Walsh; Christina Bancej; Suzanne Morin; David A Hanley; Alexandra Papaioannou
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

8.  Drug utilization in patients with OA: a population-based study.

Authors:  Nicholas Wilson; Lidia Sanchez-Riera; Rosa Morros; Adolfo Diez-Perez; M Kassim Javaid; Cyrus Cooper; Nigel K Arden; Daniel Prieto-Alhambra
Journal:  Rheumatology (Oxford)       Date:  2014-10-21       Impact factor: 7.580

9.  Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores.

Authors:  Gary S Collins; Susan Mallett; Douglas G Altman
Journal:  BMJ       Date:  2011-06-22

10.  Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.

Authors:  Hamed Khalili; Edward S Huang; Brian C Jacobson; Carlos A Camargo; Diane Feskanich; Andrew T Chan
Journal:  BMJ       Date:  2012-01-30
View more
  7 in total

1.  Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes.

Authors:  Junqing Xie; Victoria Y Strauss; Daniel Martinez-Laguna; Cristina Carbonell-Abella; Adolfo Diez-Perez; Xavier Nogues; Gary S Collins; Sara Khalid; Antonella Delmestri; Aleksandra Turkiewicz; Martin Englund; Mina Tadrous; Carlen Reyes; Daniel Prieto-Alhambra
Journal:  JAMA       Date:  2021-10-19       Impact factor: 56.272

Review 2.  Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.

Authors:  Joseph Pergolizzi; Peter Magnusson; Flaminia Coluzzi; Frank Breve; Jo Ann K LeQuang; Giustino Varrassi
Journal:  Cureus       Date:  2022-06-16

3.  Hip Fracture Risk After Treatment with Tramadol or Codeine: An Observational Study.

Authors:  Erica A Voss; Saberi Rana Ali; Arun Singh; Peter R Rijnbeek; Martijn J Schuemie; Daniel Fife
Journal:  Drug Saf       Date:  2022-07-09       Impact factor: 5.228

Review 4.  Medication use quality and safety in older adults: 2020 update.

Authors:  Tesfahun C Eshetie; Zachary A Marcum; Kenneth E Schmader; Shelly L Gray
Journal:  J Am Geriatr Soc       Date:  2021-12-13       Impact factor: 7.538

Review 5.  Perioperative Pain Management and Opioid Stewardship: A Practical Guide.

Authors:  Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary
Journal:  Healthcare (Basel)       Date:  2021-03-16

6.  Increasing Trends in Opioid Use From 2010 to 2018 in the Region of Valencia, Spain: A Real-World, Population-Based Study.

Authors:  Isabel Hurtado; Aníbal García-Sempere; Salvador Peiró; Gabriel Sanfélix-Gimeno
Journal:  Front Pharmacol       Date:  2020-12-11       Impact factor: 5.810

7.  Tramadol Versus Codeine in Hand Surgery.

Authors:  Jacob Tulipan; Jack Abboudi; Mark L Wang; Moody Kwok; Daniel Seigerman; Greg G Gallant; Pedro Beredjiklian
Journal:  Cureus       Date:  2022-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.